Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL21645281 | 0.95 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| Phosphoric Acid SCHEMBL16655013 | 0.95 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| Pyrophosphoric Acid SCHEMBL21248625 | 0.91 | LMNA (0.44) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL2180644 | 0.90 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL1896532 | 0.90 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL31070840 | 0.90 | LMNA (0.49) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7775032 | 0.89 | LMNA (0.48) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL6385398 | 0.88 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL15239320 | 0.88 | LMNA (0.47) | LMNAMTORTHRBMDM2NCOA1 | |
| SCHEMBL7196048 | 0.87 | LMNA (0.46) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015366-A1 | COMPOSITIONS AND METHODS FOR REDUCING METHANE EMISSIONS IN RUMINANT POPULATIONS | Arkea Bio Corp. (US) | 2024-01-18 | — | — | WO | claimed |
| US-20230204605-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| WO-2023077156-A1 | MODIFIED MRNA THERAPEUTICS | SHATTUCK LABS, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| CN-112176043-B | Sequencing, enrichment and detection method of modified nucleoside based on chemical marker | 北京大学 | 2022-07-12 | — | — | CN | claimed |
| EP-3099801-A1 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | Factor Bioscience Inc. (US) | 2016-12-07 | — | — | EP | claimed |
| CN-105940110-A | Methods and products for nucleic acid production and delivery | 菲克特生物科学股份有限公司 | 2016-09-14 | — | — | CN | claimed |
| EP-2914728-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | Factor Bioscience Inc. (US) | 2015-09-09 | — | — | EP | claimed |
| WO-2015117021-A1 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY | FACTOR BIOSCIENCE INC. (US) | 2015-08-06 | — | — | WO | claimed |
| WO-2014071219-A1 | METHODS AND PRODUCTS FOR EXPRESSING PROTEINS IN CELLS | FACTOR BIOSCIENCE INC. (US) | 2014-05-08 | — | — | WO | claimed |
| EP-2691101-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | Moderna Therapeutics, Inc. (US) | 2014-02-05 | — | — | EP | claimed |
| WO-2012135805-A2 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | modeRNA Therapeutics (US) | 2012-10-04 | — | — | WO | claimed |
| US-20260146264-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | FACTOR BIOSCIENCE INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260108554-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | FACTOR BIOSCIENCE INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12473594-B2 | Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement | PEKING UNIVERSITY (CN) | 2025-11-18 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-5856148-A | GENETIC ENGINEERED DNA CODING 3-PHOSPHOGLYCERATE DEHYDROGENASE; STABILITY | WACKER CHEMIE GMBH (DE) | 1999-01-05 | — | — | US | disclosed |
| US-5618716-A | ENGINEERED DNA ENCODING 3-PHOSPHOGLYCERATE DEHYDROGENASE(PGD) HAS REDUCED SENSITIVITY TO INHIBITION BY SERINE IN COMPARISION TO WILD-TYPE PGD | WACKER-CHEMIE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
| EP-0620853-B1 | MATERIALS AND METHODS FOR BIOSYNTHESIS OF SERINE AND SERINE-RELATED PRODUCTS | WACKER CHEMIE GMBH (DE) | 1996-03-06 | — | — | EP | disclosed |
| EP-0620853-A1 | MATERIALS AND METHODS FOR BIOSYNTHESIS OF SERINE AND SERINE-RELATED PRODUCTS. | WACKER CHEMIE GMBH (DE) | 1994-10-26 | — | — | EP | disclosed |
| WO-1993012235-A1 | MATERIALS AND METHODS FOR BIOSYNTHESIS OF SERINE AND SERINE-RELATED PRODUCTS | WACKER-CHEMIE GMBH (DE) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108554-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | B2M, MYADM, CD74 | LMNA 407/4885MTOR 4088/4885THRB 1295/4885 |
| US-12473594-B2 | Chemical tagging-based method for modified nucleoside sequencing, enrichment, and measurement | NT5C3B, BHMT2, NNMT | LMNA 2427/4885MTOR 4305/4885THRB 1431/4885 |
| US-20260146264-A1 | METHODS FOR REPROGRAMMING AND GENE EDITING CELLS | ZMYND8, STING1, DCLRE1A | LMNA 2027/4885MTOR 3404/4885THRB 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.